Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
---|
02/15/2011 | CA2433071C Use of transcription factor yb-1 in adenoviral systems |
02/15/2011 | CA2432177C Drug for prevention and/or therapy of endometriosis |
02/15/2011 | CA2406930C Preparation of aqueous clear solution dosage forms with bile acids |
02/15/2011 | CA2383424C Novel b7-4 molecules and uses therefor |
02/15/2011 | CA2352765C Hapten-carrier conjugates for treating and preventing nicotine addiction |
02/15/2011 | CA2247420C Combination therapy for osteoporosis |
02/15/2011 | CA2196304C Controlled local delivery of chemotherapeutic agents for treating solid tumors |
02/11/2011 | CA2675242A1 Single nucleotide polymorphisms (snps) in genes associated with inflammatory diseases |
02/10/2011 | WO2011017639A1 Methods of using c-met modulators |
02/10/2011 | WO2011016461A1 Tumor angiogenesis inhibitor |
02/10/2011 | US20110034518 Pharmaceutical composition |
02/10/2011 | US20110034379 Gastrin Compositions And Formulations, And Methods Of Use And Preparation |
02/10/2011 | US20110034377 Exendin and Exendin Agonists for Eating Disorders |
02/10/2011 | US20110033884 PD-1, A Receptor for B7-4, and Uses Therefor |
02/10/2011 | US20110033505 Methods and compositions for treatment of ion imbalances |
02/10/2011 | US20110033475 Use of beta-glucans against biological warfare weapons and pathogens including anthrax |
02/10/2011 | US20110033458 Combinations comprising epothilones and pharmaceutical uses thereof |
02/10/2011 | US20110033457 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
02/10/2011 | US20110033414 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition |
02/10/2011 | DE102009038512A1 Use of formulation comprising a substance, polyether polyol, preferably e.g. polyethylene glycol, dimethyl isosorbide, triglyceride, alcohol, preferably ethanol or isopropanol and residual water, to treat nail and/or nail bed disease |
02/10/2011 | CA2770100A1 Methods of using c-met modulators |
02/09/2011 | EP2281885A1 Combination therapy for the treatment of ocular neovascular disorders |
02/09/2011 | EP2281843A1 Antibodies that immunospecifically bind to blys |
02/09/2011 | EP2281842A1 Antibodies that immunospecifically bind to BLyS |
02/09/2011 | EP2281828A2 Compositions comprising modified erythropoietin |
02/09/2011 | EP2281578A2 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer |
02/09/2011 | EP2281568A2 Uses of soluble CTLA4 mutant molecules |
02/09/2011 | EP2281565A2 Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same |
02/09/2011 | EP2281562A2 Method of bowel cleansing |
02/09/2011 | EP2281561A2 Use of LCK inhibitors for treatment of immunologic diseases |
02/09/2011 | EP2281560A1 Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomatous optic neuropathy |
02/09/2011 | EP2280733A1 Maintenance therapy regimen for treating acne |
02/09/2011 | EP2280703A1 Use of npy y5 receptor antagonists for the prevention of psychostimulant and opioid abuse |
02/09/2011 | EP1716869B1 Drug for preventing or treating heart diseases comprising cd9 gene |
02/09/2011 | EP1451192B1 Novel crystalline compound |
02/09/2011 | EP1280898B1 Modified es cells and es cell-specific gene |
02/09/2011 | EP1011686B9 Modulation of human mast cell activation |
02/09/2011 | CN101970008A Palatable solid composition comprising antacid and saliva stimulant |
02/09/2011 | CN101970007A Therapeutic or prophylactic agent for cerebral aneurysm |
02/09/2011 | CN101969979A Apoaequorin-containing compositions and methods of using same |
02/09/2011 | CN101969961A Cholestanol derivative for combined use |
02/09/2011 | CN101969952A Methods of using and compositions comprising tryptophan hydroxylase inhibitors |
02/09/2011 | CN101969950A Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation |
02/09/2011 | CN101969947A Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with alkylating agents or anti-cd20 agents |
02/09/2011 | CN101967466A ORF7 auxotrophic varicella virus strain, vaccine containing same and application thereof |
02/09/2011 | CN101967146A Ep4 receptor inhibitors to treat rheumatoid arthritis |
02/09/2011 | CN101966338A Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist |
02/09/2011 | CN101966337A Genetic products differentially expressed in tumors and the use thereof |
02/09/2011 | CN101966183A Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
02/08/2011 | US7884179 monoclonal antibodies or antigen binding fragments that specifically to six transmembrane epithelial antigens of the prostate (STEAP-1), used for medical diagnosis, prognosis, prophylaxis and/or therapy for cancers |
02/08/2011 | US7884092 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
02/08/2011 | US7884083 Immunomodulatory compositions, methods of making, and methods of use thereof |
02/08/2011 | US7884082 Combined therapeutical treatment of hyperproliferative diseases |
02/08/2011 | US7883897 Method for producing purified hematinic iron-saccharadic complex and product produced |
02/08/2011 | US7883896 for early diagnosis, prognosis and monitoring of the disease course and for therapy and vaccination of cell proliferative disorders such as lung adenocarcinoma, lung carcinoma |
02/08/2011 | US7883880 DNA polymerase lambda and uses thereof |
02/08/2011 | US7883868 Nucleotide sequences coding beta -10 glycoprotein hormone use in diagnosis and prevention of thyroid gland disorders |
02/08/2011 | US7883729 Natural vegetable oil concentrated in unsaponifiable matters as food ingredient |
02/08/2011 | US7883725 kits comprising liquid or dry acid concentrate unit stored in first vessel, and liquid or dry citrate-containing bicarbonate concentrate unit stored in second vessel; contents of first and second vessels are emptied into dialysate preparation tank and mixed with water to form batch of dialysate |
02/08/2011 | US7883718 Methods and devices for the sustained release of multiple drugs |
02/08/2011 | US7883714 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
02/08/2011 | US7883707 Induction of antigen specific immunnologic tolerance |
02/08/2011 | US7883697 Fermented milk or vegetable proteins comprising receptor ligand and uses thereof |
02/08/2011 | US7883695 IL-12P40 and IL-B30 polypeptide complex |
02/08/2011 | US7883541 Muscle-based grafts/implants |
02/08/2011 | CA2559808C Spermicidal and virucidal properties of various forms of sophorolipids |
02/08/2011 | CA2540984C A solid dosage form comprising a fibrate |
02/08/2011 | CA2478068C Dihydropyrazole compounds useful for treating or preventing cancer |
02/08/2011 | CA2464214C Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
02/08/2011 | CA2431461C 1,5 benzothiazepines and their use as antihyperlipidemics |
02/08/2011 | CA2409854C Sustained release pharmaceutical compositions for the parenteral administration of biologically active hydrophilic compounds |
02/08/2011 | CA2341574C Phosphohalohydrins, method for making same and uses |
02/08/2011 | CA2273825C Cytopathic viruses for therapy and prophylaxis of neoplasia |
02/08/2011 | CA2223407C Oxidant scavengers |
02/08/2011 | CA2199940C Anti-receptor and growth blocking agents to the vitamin b12/transcobalamin ii receptor and binding sites |
02/03/2011 | WO2011013786A1 Cancer metastasis inhibitor |
02/03/2011 | WO2011013698A1 Carrier peptide fragment and use thereof |
02/03/2011 | WO2011013668A1 Pharmaceutical composition for treatment of ischemic events |
02/03/2011 | WO2011012626A1 Compositions comprising thalidomide and artemisinin for the treatment of cancer |
02/03/2011 | WO2011012585A1 Mutants pf4 polypeptides exhibiting an increased anti-angiogenic activity |
02/03/2011 | WO2010111136A9 Aliskiren modulation of neurogenesis |
02/03/2011 | WO2010060937A3 Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor |
02/03/2011 | US20110028807 Contact lens for collecting tears and detecting at least one analyte |
02/03/2011 | US20110028543 Formulations and methods of using nitric oxide mimetics in cancer treatment |
02/03/2011 | US20110027883 Rna interference mediating small rna molecules |
02/03/2011 | US20110027369 Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients |
02/03/2011 | US20110027310 Compositions and Methods for Cancer Treatment |
02/03/2011 | US20110027182 Substance for obtaining highly effective tumor medications as well as a process |
02/03/2011 | US20110027180 Detection and treatment of prostate cancer |
02/03/2011 | DE102009035586A1 Intravesikale Instillationslösungen zur Behandlung von Blasenkrebs Intravesical instillation to treat bladder cancer |
02/03/2011 | CA2769012A1 Compositions comprising thalidomide and artemisinin for the treatment of cancer |
02/02/2011 | EP2280012A2 Pyrrolo[2,1-f][1,2,4]triazine derivatives as kinase inhibitors |
02/02/2011 | EP2279750A1 Aniline derivative having anti-rna viral activity |
02/02/2011 | EP2279742A2 Combinations for the treatment of immunoinflammatory disorders |
02/02/2011 | EP2279734A1 Composition for preventing cardiovascular event in high-risk patient |
02/02/2011 | EP2279732A2 Compounds and compositions for delivering active agents |
02/02/2011 | EP2279244A2 Methods and compositions for oral administration of proteins |
02/02/2011 | EP2278992A2 Therapy for vitiligo |
02/02/2011 | EP1343520B1 New therapeutic uses of smr1 peptides |
02/02/2011 | EP1039893B1 Pharmaceutical compositions containing an omega-3 fatty acid oil |